Although demethylating agents and BCL-2 inhibitors significantly improve remission rates in patients with this disease, most still relapse after 2–3 years, especially patients with high-risk MDS (HR-MDS); no clinically effective treatment is available for preventing disease progression to acute leukemia. Here, BCL2 is linked to myelodysplastic syndrome.